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The conundrum of neuroendocrine liver metastases
For the HPB surgeon, neuroendocrine liver metastases present an interesting challenge since patients are often well or indeed
asymptomatic despite an extensive tumour burden. Guidance on the need for intervention is lacking and outcomes are
difficult to assess since the disease may be associated with long term survival without intervention. In this issue ofHPB, three
review articles attempt to provide some guidance following a consensus conference held at the initiative of the E-AHPBA in
London in 2012. The large attendance at this meeting demonstrated the thirst for new evidence but the process suggested
that much of what is published is repetitive, anecdotal and of a low level of evidence. The systematic review by Lesurtel and
colleagues highlights this very fact. Of 1594 reports available for review, only 38 were relevant for analysis. Remarkably only
two of these focused on quality of life issues. There was little evidence to support debulking of liver metastases or to suggest
that liver resection was better than other liver directed therapies. Eighteen of the 115 papers considered to be of relevance
by Kennedy et al, showed that intra-arterial therapy is used extensively and that embolization is generally well tolerated, but
again, there is little reliable evidence to suggest that it has impact on survival. The review notes increasing interest in
radioembolisation but its popularity is again not necessarily evidence based. So what about taking the liver out and replacing
it? Fan and his colleagues reviewed an extensive database and established that the 706 patients who were recorded as having
undergone liver transplantation for disease confined to the liver had done well with a 70% five year survival. This is good
news for those few selected patients worldwide. However, the observation that patients with tumours that are not poorly
differentiated and that have been assessed over a period of at least 6 months will benefit most would suggest that this is not
a mode of treatment that can be readily extended. Furthermore, such patients will generally do well if merely observed, so
are we really any further forward? That is the conundrum!
James Garden
Bile leak after liver resection
While death after liver resection is reported at ever lower levels, complication rates remain stubbornly high. Morbidity is
associated with longer intensive care and hospital stay, and poorer oncological outcomes. Variability in the reported rate of
complications may partly be due to differences in definitions. The International Study Group for Liver Surgery (ISGLS) has
now published definitions in three areas: liver failure and haemorrhage after hepatectomy, and bile leak after liver surgery.
These have stimulated debate and different predictive models vie for supremacy. In this issue, Brooke-Smith and colleagues
from the ISGLS use their definition and grading system to prospectively evaluate bile leak after liver resection.
Of 949 patients in 11 centres undergoing liver resection for predominately colorectal liver metastases, 7.3% were
diagnosed with a bile leak. Of these, just over half required something done about it. ‘If you don’t take a temperature you
can’t find a fever’, a medical truism from Samuel Shem’s 1978 novel The House of God, equally applies here: grade A bile leaks
requiring no/little change in patients’ management are only diagnosed in the presence of an abdominal drain. Of course, a
patient without a drain found to have a bile leak, by definition, has a grade B leak. Yet, even in those with seemingly
inconsequential grade A bile leaks, a greater number and severity of other complications were seen, together with a longer
hospital stay (median 14 versus 7 days on average). Indeed, bile leak was significantly associated with intra-operative blood
loss which may explain these poor outcomes.
There is little strong evidence supporting drainage after liver resection, yet in this series drains were used in 64% of
patients. In nearly half of patients with a bile leak and a drain, there was no significant change in the clinical course; the
authors suggest that up to 94% of patients did not benefit from intra-operative drainage.
In this up-to-date series, the overall complication rate of 38% is striking. Although only 8.8% of complications were
classified as severe, this rate is not improving. Interventions to reduce this rate should surely be a priority in seeking to
improve long-term liver resection outcomes.
Ewen Harrison
Local resection of T1 ampullary adenocarcinoma – less is not always more
The more favorable biology of ampullary adenocarcinoma as compared to pancreatic adenocarcinoma, and the ability to
perform ampullectomy via endoscopic approaches has led to the application of local resection alone for T1 ampullary
adenocarcinoma. In this issue of HPB, Amini and colleagues report the results of a population level study assessing the
impact of performing local resection alone for T1 ampullary adenocarcinoma utilizing the Surveillance, Epidemiology, and
End Results (SEER) database. Of 421 eligible patients with T1 disease, 21 (5%) patients underwent local resection alone,
while 20 (5%) patients were treated with ampullectomy and regional lymphadenectomy, and 163 (39%) patients with
pancreaticoduodenectomy (PD). Interestingly, 217 patients (51%) did not undergo resection of any kind, resulting in a
median survival of only 16 months. In patients who underwent concomitant lymphadenectomy, metastatic lymph nodes
were present 20% of the time consistent with prior studies; and even patients with well-differentiated histology, who would
be potentially the best candidates to consider for local resection alone, had metastatic lymph nodes present 10% of the time.
The addition of regional lymphadenectomy, either concomitant with local resection or with PD, for T1 ampullary adeno-
carcinoma improved survival significantly regardless of lymph node status as compared to local resection alone. This study
provides further credence to the importance of performing regional lymhadectomy for ampullary adenocarcinoma, even for
early stage disease. The obvious extension of this work is further support that endoscopic ampullectomy for T1 lesions is not
an equivalent or appropriate approach for fit patients. However, for patients who refuse surgery or who are not medically
fit, endoscopic ampullectomy may still offer a significant survival advantage as the median survival in the present study with
local resection alone was 55 months. Thus, though not a focus of this study, the finding that 51% of patients are treated with
surveillance alone in this population based study may represent an opportunity for intervention with positive benefits for
patients with this disease that are presently unrealized.
Rebecca Minter
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